KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Net Margin (2017 - 2025)

Moderna (MRNA) has disclosed Net Margin for 9 consecutive years, with 121.83% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 589.0% to 121.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 145.16% through Dec 2025, down 3287.0% year-over-year, with the annual reading at 145.16% for FY2025, 3512.0% down from the prior year.
  • Net Margin for Q4 2025 was 121.83% at Moderna, down from 19.69% in the prior quarter.
  • The five-year high for Net Margin was 67.51% in Q4 2021, with the low at 899.07% in Q1 2025.
  • Average Net Margin over 5 years is 166.34%, with a median of 2.47% recorded in 2024.
  • The sharpest move saw Net Margin skyrocketed 161304bps in 2021, then plummeted -70784bps in 2024.
  • Over 5 years, Net Margin stood at 67.51% in 2021, then tumbled by -57bps to 28.82% in 2022, then crashed by -73bps to 7.72% in 2023, then tumbled by -1602bps to 115.94% in 2024, then decreased by -5bps to 121.83% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 121.83%, 19.69%, and 580.99% for Q4 2025, Q3 2025, and Q2 2025 respectively.